SciELO - Scientific Electronic Library Online

vol.147 número1Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyéticoCaracterización de cepas clínicas y ambientales de Salmonella enterica subsp. enterica serovar Heidelberg aisladas en Chile índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google


Revista médica de Chile

versão impressa ISSN 0034-9887


MENDOZA, María Gabriela et al. Primary plasma cell leukemia. Report of five cases. Rev. méd. Chile [online]. 2019, vol.147, n.1, pp.18-23. ISSN 0034-9887.


Primary plasma cell leukemia (pPCL) is uncommon, aggressive and has a different biology than multiple myeloma (MM).


To report the features of patients with pPCL.

Material and Methods:

Review of databases of the Hematology Department and the Hematology laboratory.


Of 178 patients with monoclonal gammopathies, five (2.8%) patients aged 33 to 64 years (three females) had a pPCL. The mean hemoglobin was 7.3 g/dL, the mean white blood cell count was 52,500/mm3, with 58% plasma cells, and the mean platelet count was 83,600/mm3. The mean bone marrow infiltration was 89%, LDH was 2,003 IU/L, serum calcium was 13 mg/dL, and creatinine 1.5 mg/dL. Two patients had bone lesions. Three were IgG, one IgA lambda and one lambda light chain. CD20 was positive in one, CD56 was negative in all and CD117 was negative in 3 cases. By conventional cytogenetic analysis, two had a complex karyotype. By Fluorescence in situ Hybridization, one was positive for TP53 and another for t (11; 14). One patient did not receive any treatment, three patients received VTD PACE and one CTD. None underwent transplant. Three patients are alive. The mean survival was 14 months.


These patients with pPCL were younger and had a more aggressive clinical outcome than in multiple myeloma.

Palavras-chave : Bortezamib; Leukemia, Plasma Cell; Paraproteinemias.

        · texto em Espanhol     · Espanhol ( pdf )